Log in to search using one of your social media accounts:

 

Ovarian Fallopian Tube Primary Peritoneal Cancer
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news

ovarian epithelial fallopian cancer
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news

It ’ s your body, it ’ s your choice – Louise ’ s story
The post It’s your body, it’s your choice – Louise’s story appeared first on Hysterectomy Association. I woke up the day after my work Christmas party with, not the raging hangover some of my colleagues might have, but dreadful pains across my lower half, the small of my back and down my left leg. My period was due, and being 48, I thought this could be the peri-menopause too! Joys of being a woman! But I really didn’t give it an awful lot of thought. But the pains got worse. I was working as a teacher in Hanoi, Vietnam where all healthcare is paid for, and appointments are always available. I...
Source: The Hysterectomy Association - April 10, 2017 Category: OBGYN Authors: Linda Tags: Your Stories endometriosis ovarian cyst Source Type: news

FDA Approves Niraparib for Recurrent Ovarian Cancer
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news

FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 27, 2017 Category: American Health Source Type: news

Tesaro wins FDA approval for potential blockbuster cancer drug
The FDA has approved a cancer drug developed by Waltham-based Tesaro that some analysts believe could surpass $2 billion in peak sales. Shares of Tesaro (Nasdsaq: TSRO) were halted Monday afternoon prior to the FDA’s announcement. The drug, niraparib, will be sold under the brand name Zejula. The 430-employee company previously said that regulators would issue a decision in mid-2017. In addition to being early, the approval is broad, covering patients with ovarian, fallopian tube, and primary… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 27, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Maintenance Chemo After CR Fails to Extend Survival in Ovarian Cancer
A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news

Bevacizumab Approved for Another Type of Ovarian Cancer Bevacizumab Approved for Another Type of Ovarian Cancer
The latest FDA approval is for use in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: World Pharma News)
Source: World Pharma News - December 9, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Media News)
Source: Roche Media News - December 7, 2016 Category: Pharmaceuticals Source Type: news

Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2016 Category: Pharmaceuticals Source Type: news

I am a Hypochondriac
I am in a perpetual abusive relationship with hypochondria; I desperately want to get away from it, but somehow it controls my brain. I've had hypochondriac tendencies (more officially known as "illness anxiety disorder") for as long as I can remember. I'm not sure who or what to blame and the source of the disorder is irrelevant; it's the cure I'm after. Hypothesis theories for my hypochondria: Throughout my childhood, my mother perpetually complained of a bad heart and threatened to faint, falling back on her stash of smelling salts in her purse. The best birthday present I ever got was the Merck Medical Ma...
Source: Healthy Living - The Huffington Post - September 30, 2016 Category: Consumer Health News Source Type: news

The 1 Thing You Need To Stop Doing To Your Vagina
For SELF, by Zahra Barnes. A scary new report adds one more item to the “why women shouldn’t douche” list. Gynecologists have been telling their patients not to clean their vaginas with douches for years—and now they have yet another strong point against it: The practice is associated with nearly a doubled risk of getting ovarian cancer, according to a large study from the National Institute of Environmental Health Sciences. “Douching is just wrong,” Sherry Ross, M.D., an ob/gyn and women’s health expert at Providence Saint John’s Health Center in Santa M...
Source: Healthy Living - The Huffington Post - August 16, 2016 Category: Consumer Health News Source Type: news

Stealthy early-stage NVision Medical raises $6.5m
Stealthy NVision Medical raised $6.5 million in a new round of equity financing to support its ovarian cancer diagnostic device, according to an SEC filing. NVision is an early-stage medical device company focused on women’s health, specifically creating in-office diagnostics for ovarian cancer and fallopian tube blockages, according to a 2014 interview with MedCity News. The company was incorporated in 2009, is based in San Francisco, Calif., and is run by founder and CEO Surbhi Sarna. Money in the round came from 17 unnamed sources, and the company is still looking for another $5.5 million before closing, according...
Source: Mass Device - July 22, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Women's Health NVision Source Type: news

BRCA1 mutations linked to increased risk of serous, serous-like endometrial cancer
(The JAMA Network Journals) Increased risk for aggressive serous/serous-like endometrial cancer was increased in women with BRCA1 mutations, although the overall risk for uterine cancer after risk-reducing salpingo-oophorectomy (RRSO) to remove the fallopian tube and ovary was not increased, according to a new study published online by JAMA Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 30, 2016 Category: Cancer & Oncology Source Type: news

Research uncovers more inherited genetic mutations linked to ovarian cancer
(Care New England ) Previous research has established a link between genetic mutations in the BRCA1 and BRCA2 genes to an increased risk of developing ovarian, fallopian tube or peritoneal cancer in women. A recent publication documents the efforts of a team of researchers affiliated with the Gynecologic Oncology Group (GOG) to determine if inherited genetic mutations other than BRCA1 and BRCA2 can also put a woman at risk of developing these diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2016 Category: Cancer & Oncology Source Type: news

Fallopian tube organoids promise better understanding of ovarian cancer, infertility
A new way of growing fallopian tube cells in culture is expected to give a boost to our understanding and prevention of female genital diseases, such as infertility, inflammatory disease, and ovarian cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 11, 2015 Category: Science Source Type: news

Fallopian tube organoids promise better understanding of ovarian cancer and infertility
(Max-Planck-Gesellschaft) A new way of growing Fallopian tube cells in culture is expected to give a boost to our understanding and prevention of female genital diseases, such as infertility, inflammatory disease, and ovarian cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2015 Category: Global & Universal Source Type: news

That Time My Ovary Grew Something It Shouldn't, Twice
I felt it jolt me awake and suddenly I knew I couldn't really move. My stomach was clenched tight from the stabbing sensation, my legs were curled, and I laid there in a fetal position in our bed waking my fiancé up with my groaning. "Do you need a Gas X again or suppository? I told you not to eat all that ice cream," she mumbled half-asleep like she's had to every other night for years because I'm a stubborn fat ass. Though it was very possible Chocolate Malted Crunch was to blame, something told me it was something else. And I was right. Later at the hospital that day, we learned I had ruptured an ovaria...
Source: Science - The Huffington Post - December 3, 2015 Category: Science Source Type: news

Olivia Key who looked pregnant discovers a cancerous cyst is to blame
Olivia Key, 18, of Hull, had surgery to remove the cancerous ovarian cyst, which weighed one and a half stone - heavier than a newborn baby. She also had her ovary and fallopian tube removed. (Source: the Mail online | Health)
Source: the Mail online | Health - December 3, 2015 Category: Consumer Health News Source Type: news

Leeds girl astonished when tests reveal a 30cm cyst and ovarian cancer
Olivia Key, now 18, from Hull, was rushed into surgery at St James's Hospital in Leeds where medics removed the growth as well as her ovary and fallopian tube. (Source: the Mail online | Health)
Source: the Mail online | Health - November 16, 2015 Category: Consumer Health News Source Type: news

New method enables the early detection of ovarian cancer
Around 75 per cent of ovarian tumors arise from the fallopian tube. There are currently no options for detecting this condition early or preventing it. With the help of an innovative, "three-way" catheter, a new study suggests that this situation may be different in the future. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 10, 2015 Category: Science Source Type: news

Maidstone woman who doctors believed was pregnant had cancerous tumour
Louise Bryant, 26, of Maidstone, had an immature teratoma, a rare type of ovarian cancer. She underwent a four hour operation to remove the 20cm growth and her fallopian tube. (Source: the Mail online | Health)
Source: the Mail online | Health - July 20, 2015 Category: Consumer Health News Source Type: news

NICE issues ACD on bevacizumab for recurrent advanced platinum sensitive or partially platinum sensitive ovarian, fallopian tube, and primary peritoneal cancer
Source: NICE Area: News The National Institute for Health and Clinical Excellence (NICE) has issued for consultation an Appraisal Consultation Document (ACD) on the use of bevacizumab for treating advanced ovarian cancer that has returned six months or more after initial treatment with platinum-based chemotherapy (platinum-sensitive disease).   The following preliminary recommendations have been made:   . Bevacizumab in combination with gemcitabine and carboplatin is not recommended for treating the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary ...
Source: NeLM - News - February 1, 2013 Category: Drugs & Pharmacology Source Type: news